Keywords
How to Cite
Abstract
As every year, our discipline has progressed in each of its areas, most often with changes, but sometimes also new orientations having an impact on daily practice. The selection presented here includes a few publications that have drawn attention to developments or limits in our practices over the past year.
References
Bularga A, Hung J, Daghem M, et al. Coronary artery and cardiac disease in patients with type 2 myocardial infarction: a prospective cohort study. Circulation 2022; 145:1188-200.
Garcia S, Dehghani P, Stanberry L, et al. Trends in clinical presentation, management, and outcomes of STEMI in patients with Covid-19. J Am Coll Cardiol 2022; 79:2236-44.
Han Y, Liao Z, Li Y, et al. Magnetically controlled capsule endoscopy for assessment of antiplatelet therapy-induced gastrointestinal bleeding. J Am Coll Cardiol 2022; 79: 116-28.
Fearon WF, Zimmermann FM, De Bruyne B, et al. Fractional flow reserve-guided PCI as compared with coronary bypass surgery. N Engl J Med 2022; 386: 128-37.
Gaudino M, Di Franco A, Alexander JH, et al. Sex differences in outcomes after coronary artery bypass grafting: a pooled analysis of individual patients data. Eur Heart J 2022: 43: 18-28.
Lindholt JS, Soggard R, Rasmussen LM, et al. Five-year outcomes of the Danish Cardiovascular Screening (DANCAVAS) trial. N Engl J Med 2022. 387: 1385-94.
Nguyen V, Willner N, Eltchaninoff H, et al. Trends in aortic valve replacement for aortic stenosis: a French nationwide study. Eur Heart J 2022; 43: 666-79.
Durand E, Sacri C, Levesque T, et al. Incidence, predictive factors, and prognostic impact of right ventricular dysfunction before transcatheter aortic valve replacement. Am J Cardiol 2022; 161: 63-9
Hahn J, Virk HUH, Al-Azzam F, et al. Outcomes of transcatheter aortic valve implantation in patients with chronic and end-stage kidney disease. Am J Cardiol 2022; 164: 100-2.
Mangner N, del Val D, Abdel-Wahab M, et al. Surgical treatment of patients with infective endocarditis after aortic valve implantation. J Am Coll Cardiol 2022; 79: 772-85.
Tribouilly C, Bohbot Y, Kubala M, et al. Characteristics, management, and outcomes of patients with multiple native valvular heart disease : a substudy of the EURObservational Research Program Valvular Heart Disease II Survey. Eur Heart J 2022 ; 43 : 2756-66.
Gammie JS, Chu MWA, Falk V, et al. Concomitant tricuspid repair in patients with degenerative mitral regurgitation. N Engl J Med 2022; 386: 327-39.
Özkan M, Gündüz S, Güner A, et al. Thrombolysis or surgery in patients with obstructive mechanical valve thrombosis: the multicenter HATTUSHA Study. J Am Coll Cardiol 2022; 79: 977-89.
Banhson TD, Giczewska A, Mark DB, et al. Association between age and outcomes of catheter ablation versus medical therapy for atrial fibrillation. Results from the CABANA trial. Circulation 2022; 145: 796-804
Deitelzweig S, Sah J, Kang A, et al. Effectiveness and safety of apixaban versus warfarin in obese patients with nonvalvular atrial fibrillation enrolled in Medicare and Veteran Affairs. Am J Cardiol 2022; 163 : 43-9
Osmancik P, Herman D, Neuzil P, et al. 4-year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation. J Am Coll Cardiol 2022; 79: 1-14.
Labori F, Persson J, Bonander C, et al. Cost-effectiveness analysis of left atrial appendage occlusion in patients with atrial fibrillation and contraindication to oral anticoagulation. Eur Heart J 2022; 43: 1348-56.
Karam N, Pechmajou L, Narayanan K, et al. Evolution of incidence, management, and outcomes over time in sports-related sudden cardiac arrest. J Am Coll Cardiol 2022; 79: 238-46.
Nordenswan HK, Pöihönen P, Lehtonen J, et al. Incidence of sudden cardiac death and life-treatening arrhythmias in clinically manifest cardiac sarcoidosis with and without current indication for an implantable cardioverter defibrillator. Circulation 2022; 166: 964-75.
Steinberg C, Dognin N, Sodhi A, et al. DREAM-ICD-II Study. Circulation 2022; 145 : 742-53.
Zheng J, Heidenreich PA, Kohsaka S, et al. Variability in coronary artery disease testing for patients with new-onset heart failure. J Am Coll Cardiol 2022; 79: 849-60.
Von Lewinski , Kolesnik E, Tripolt NJ, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J 2022; 41: 4421-32.
Shah SJ, Borlaug BA, Chung ES, et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomized, multicenter, blinded, sham-controlled trial. Lancet 2022; 399: 1130-40.
Cheng CY, Baritussio A, Giordani AS, et al. Myocarditis in systemic immune-mediated diseases: prevalence, characteristics, and prognosis: a systematic review. Autoimm Rev 2022; 21: doi: 10.1016/j.autrev.2022.103037.
Totzeck M, Michel L, lin Y, et al. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. Eur Heart J 2022; 43: 1928-40.
Patone M, Mei XW, Hanndunnetthi, L, et al. Risks of myocarditis, pericarditis, and cardiac arrhytmias associated with Covid-19 vaccination or Sars-CoV2 infection. Nat Med 2022 ; 28 : 410-22.
McKenzie I, Rogers A, Poulter NR, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK : a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet 2022; 400: 1417-25.
Wang G, Bhatta L, Moen GH, et al. Investigating a potential causal relationship between maternal blood pressure during pregnancy and future offspring cardiometabolic health. Hypertension 2022; 79: 170-7.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Medical Focus Journal